Skip to main content

Table 3 Regression models predicting the use of tocilizumab monotherapy, odds ratios (95% confidence intervals)

From: The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy

  Total population No prior tocilizumab combination (n = 6821) Ever prior tocilizumab combination (n = 448)
Baseline only Baseline and follow-up Baseline and follow-up Baseline and follow-up
Age, per year 0.99 (0.98, 1.00) 1.04 (1.00, 1.08) 1.03 (0.99, 1.07) 1.03 (1.00, 1.06)
Male vs. female 0.82 (0.61, 1.11) 0.72 (0.24, 2.19) 1.01 (0.30, 3.37) 0.67 (0.30, 1.53)
Disease duration, per year 0.99 (0.98, 1.01) 1.04 (1.00, 1.07) 1.04 (1.00, 1.08) 1.05 (0.99, 1.10)
Serologic status*
Negative Reference    
Positive 0.73 (0.57–0.93) 2.82 (0.46, 17.2) 0.38 (0.07, 2.18) 1.36 (0.27, 6.69)
Missing 0.50 (0.29–0.84) 9.58 (1.85, 49.7) 1.72 (0.39, 7.67) 0.99 (0.33, 3.03)
DMARD use**
csDMARD, baseline 0.48 (0.37–0.63)
TCZ combination 327 (80, 1343)
TNFi 0.21 (0.09, 0.49) 0.28 (0.11, 0.73) 0.08 (0.03, 0.21)
nonTNFi nonTCZ bDMARD 1.73 (0.86, 3.50) 2.70 (1.25, 5.85) 0.17 (0.07, 0.37)
Only csDMARD 0.94 (0.36, 2.47) 1.16 (0.40, 3.39) 2.76 (1.18, 6.47)
No DMARDs 0.05 (0.01, 0.16) 0.09 (0.03, 0.33) 0.02 (0, 0.12)
Glucocorticoid use 0.74 (0.39, 1.40) 0.91 (0.46, 1.78) 0.91 (0.46, 1.78)
CDAI, severe Reference Reference Reference
Moderate 0.43 (0.23, 0.78) 0.41 (0.22, 0.79) 0.44 (0.17, 1.17)
Low 0.39 (0.21, 0.74) 0.40 (0.20, 0.79) 0.70 (0.29, 1.70)
Remission 0.17 (0.07, 0.42) 0.11 (0.04, 0.32) 0.53 (0.18, 1.52)
Comorbidities, count# 1.04 (0.98, 1.11) 1.09 (1.01, 1.18) 1.01 (0.92, 1.11)
  1. Notes: Odds ratios (95% confidence intervals). Baseline models used logistic regression. Models with follow-up data used mixed generalized linear regression
  2. TCZ tocilizumab; DMARD disease-modifying anti-rheumatic drug; csDMARDs conventional synthetic DMARDs; nonTNFi nonTCZ bDMARD includes all JAK inhibitors, abatacept, and rituximab
  3. ---Not considered at baseline or not significant in univariable screen so not considered in multivariable model or withheld from the model because of problems with convergence
  4. *Serologic status defined as a positive if either rheumatoid factor or anti-CCP antibody were ever positive up to the relevant reference point
  5. **Reference category for DMARD use is the non-use of a give DMARD
  6. #Comorbidities are noted in Table 1. Clinical disease activity index (CDAI) categories defined as remission (CDAI < 2.8), low (CDAI 2.9–10.0), moderate (CDAI 10.1–22.0), and high (CDAI > 22.1)